Immune responses to guided imagery during breast cancer treatment

Biol Res Nurs. 2008 Jan;9(3):205-14. doi: 10.1177/1099800407309374.

Abstract

Background: The use of relaxation and guided imagery to reduce stress and improve immune function has great potential benefits for patients with breast cancer.

Methods: This pilot study used a pretest-posttest experimental design with 28 breast cancer patients, aged 25 to 75 years, with the diagnosis of stage 0, 1, or 2 breast cancer. The experimental group received a relaxation and guided imagery intervention and the control group received standard care. The effects of the intervention on immune function were measured by natural killer (NK) cell cytotoxicity and IL-2-activated NK cell activity prior to surgery and 4 weeks postsurgery. NK cell activity was measured using a 15-hr incubation chromium release assay. Cytotoxicity of NK cells was measured against chromium-labeled K-562 target cells. IL-2 was used to enhance reactivity of NK cells against tumor cells. After incubation for 15 hr, cytotoxicity was measured through the release of radioactive chromium.

Results: Significant differences between groups were found at 4 weeks postsurgery. T-tests showed increased NK cell cytotoxicity for the intervention group at 100:1, 50:1, and 25:1 effector cell: target cell ratios (E:T) (p < .01 to p < .05) and increased activation for IL-2 at 100:1, 50:1, 25:1, and 12.5:1 (E:T) (p < .01 to p < .05) for the intervention group as compared to the control group.

Discussion: These findings suggest that a relaxation intervention such as guided imagery could have an effect on NK cell cytotoxicity and NK cell cytotoxicity after activation with IL-2 in patients undergoing surgery for breast cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Breast Neoplasms / immunology*
  • Breast Neoplasms / psychology
  • Breast Neoplasms / therapy
  • Female
  • Humans
  • Imagery, Psychotherapy*
  • Interleukin-2 / immunology
  • Killer Cells, Natural / immunology
  • Middle Aged

Substances

  • Interleukin-2